Guardant blood test detects 83% of colorectal cancer cases, but fewer in early stage

Guardant Health on Tuesday presented results of a pivotal study of Shield, its blood-based test for colorectal cancer, demonstrating an overall sensitivity of 83% and specificity of 90%.